Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jon Wesley

Vascular Surgery Orlando, FL Medical Doctor

NPI 1538149331 CMS profile 160644

80 W Michigan St, Orlando, FL 32806

Open in the dashboard

General payments

$21,940

199 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jon Wesley of Orlando, FL is reported in the CMS Open Payments database as having received $21,940 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,720 18
2024 General $2,535 32
2023 General $3,482 27
2022 General $1,830 32
2021 General $1,342 24
2020 General $1,020 25
2019 General $10,011 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jon Wesley
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Jon Wesley were reported at $1,720. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Jon Wesley Vascular Surgery median Middle half National median
2019 $10,011 $796 $226–$2,363 $163
2020 $1,020 $348 $118–$1,110 $114
2021 $1,342 $471 $158–$1,421 $132
2022 $1,830 $725 $222–$2,183 $149
2023 $3,482 $836 $257–$2,440 $160
2024 $2,535 $909 $252–$2,619 $164
2025 $1,720 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $8,234 12 payments
  2. Silk Road Medical, Inc. $3,162 38 payments
  3. AngioDynamics, Inc. $1,941 3 payments
  4. Penumbra, Inc. $1,564 7 payments
  5. Boston Scientific Corporation $1,394 19 payments
  6. W. L. Gore & Associates, Inc. $1,380 31 payments
  7. Endologix, Inc. $693 8 payments
  8. Bard Peripheral Vascular, Inc. $532 10 payments
  9. Siemens Medical Solutions USA, Inc. $350 3 payments
  10. Cardiovascular Systems Inc. $316 10 payments
  11. Other $2,374 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $10,420 12 payments
  2. Food and Beverage $9,450 184 payments
  3. Long term medical supply or device loan $1,920 2 payments
  4. Education $150 1 payment
Products named General payments · program years 2019–2025
  1. IN.PACT Admiral $7,990 7 payments
  2. ENROUTE Transcarotid Stent $3,162 38 payments
  3. ENROUTE Transcarotid Neuroprotection System $3,162 38 payments
  4. Indigo System $1,395 4 payments
  5. VenaCure 1470 Pro Et $960 1 payment
  6. VenaCure 1470 Pro Id $960 1 payment
  7. General Therapies $878 6 payments
  8. ENHANCE Transcarotid Peripheral Access Kit $493 9 payments
  9. ENROUTE .014 Guidewire $493 9 payments
  10. Alto Abdominal Stent Graft System $448 4 payments
  11. Other $8,072 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

299

Median for Vascular Surgery: 122

Drug cost

$30,788

Median for Vascular Surgery: $14,135

Branded share of claims

55.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $21,232
Xarelto Rivaroxaban Brand 11 $6,280
Cilostazol Generic 79 $1,448
Clopidogrel Clopidogrel Bisulfate Brand 130 $1,027
Pentoxifylline Generic 13 $484
Gabapentin Generic 30 $290
Oxycodone Hcl Generic 12 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 118 billing codes

Paid by Medicare

$186,509

Of which drugs: $7,102

Medicare patients

389

Average age 76

Services billed

2,431

170 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Chronic kidney disease 58%
Arthritis 54%
Diabetes 51%
Heart failure 38%
COPD 33%
Atrial fibrillation 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 14 563 $163

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record